心脏人工瓣膜置换术后孕妇的围产期抗凝管理  

Perinatal anticoagulation management of pregnant women with cardial prosthetic valve replacement

作　　者：黄滔滔[1] 林建华[1] 

机构地区：[1]上海交通大学医学院附属仁济医院妇产科,上海200127

出　　处：《中国实用妇科与产科杂志》2017年第7期667-671,共5页Chinese Journal of Practical Gynecology and Obstetrics

摘　　要：心脏人工瓣膜置换术后的患者妊娠属于高危妊娠,孕前详细评估心脏病的情况,孕期多学科联合管理,根据患者的病史、瓣膜状况、抗凝药物剂量、孕周等综合分析,选择恰当的抗凝方案,密切监测病情并维持和调整凝血状态,围分娩期预先计划调整好凝血功能,以确保母儿安全。Pregnancy of women with cardial prosthetic valve replacement belongs to high-risk pregnancy.To ensure the safety of both mother and fetus,assessment of heart disease before pregnancy and multidisciplinary management during pregnancy should be done.At the same time,we should select appropriate anticoagulation therapy,monitor the condition closely and maintain the stability of coagulation state,and adjust the coagulation function in advance according to the comprehensive analysis of patients＇ medical history,valvular status,anticoagulant dose and gestational weeks.

关 键 词：心脏病 瓣膜置换 抗凝 血栓形成 围产期 

分 类 号：R654.2[医药卫生—外科学]